Clinical trial
A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
NCT04235621 is registered in ClinicalTrials.gov with Goldfinch Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Characterize the Genetic, Biomarker, and Clinical Profile of Patients With Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
- Lead sponsor
- Goldfinch Bio, Inc.
- Phase
- Observational
- Overall status
- Terminated
- Start date
- December 20, 2019
- Completion date
- May 27, 2020
- Enrollment
- 20 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic nephropathies, glomerulosclerosis, focal segmental, minimal change disease